Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
This study will evaluate the safety and immunogenicity of VAX102 \[Flagellin.HuM2e\], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
Epistemonikos ID: 683da2d29ca1d55d8fb0d9a9242837991f814128
First added on: May 04, 2024